{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T10:07:35Z","timestamp":1770286055072,"version":"3.49.0"},"reference-count":27,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2015,1,3]],"date-time":"2015-01-03T00:00:00Z","timestamp":1420243200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Rheum Dis"],"published-print":{"date-parts":[[2015,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aim<\/jats:title><jats:p>The aim of this study was to investigate the incidence of tuberculosis (<jats:styled-content style=\"fixed-case\">TB<\/jats:styled-content>) following anti\u2010tumor necrosis factor (<jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>) therapy in an intermediate<jats:styled-content style=\"fixed-case\">TB<\/jats:styled-content>burden area and to compare the risk between drugs and diseases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The data were obtained from a nationwide database maintained by the Health Insurance Review and Assessment Service. The study population comprised of patients who were prescribed with<jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>inhibitors from 2005 to 2009.<jats:styled-content style=\"fixed-case\">TB<\/jats:styled-content>cases were selected based on prescription of anti\u2010<jats:styled-content style=\"fixed-case\">TB<\/jats:styled-content>medications.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 8421 patients in the study population, 1729 patients with latent<jats:styled-content style=\"fixed-case\">TB<\/jats:styled-content>prophylaxis were identified and 102 patients developed<jats:styled-content style=\"fixed-case\">TB<\/jats:styled-content>. The incidence of<jats:styled-content style=\"fixed-case\">TB<\/jats:styled-content>was 1017 per 100\u00a0000 person\u2010years. When divided into four groups according to the main diagnosis and using an ankylosing spondylitis group as a reference, the incidence of<jats:styled-content style=\"fixed-case\">TB<\/jats:styled-content>was highest in patients with inflammatory bowel disease (<jats:styled-content style=\"fixed-case\">IBD<\/jats:styled-content>) (incidence rate ratio [<jats:styled-content style=\"fixed-case\">IRR<\/jats:styled-content>] 5.97, 95% confidence interval [<jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>] 3.34\u201310.66), followed by patients with rheumatoid arthritis (<jats:styled-content style=\"fixed-case\">IRR<\/jats:styled-content>1.02, 95%<jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>0.57\u20131.83) and those with psoriatic arthritis (<jats:styled-content style=\"fixed-case\">IRR<\/jats:styled-content>1.00, 95%<jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>0.14\u20137.30). Comparison between drugs showed a significantly lower incidence of<jats:styled-content style=\"fixed-case\">TB<\/jats:styled-content>in patients treated with etanercept (reference), highest incidence in those treated with infliximab (<jats:styled-content style=\"fixed-case\">IRR<\/jats:styled-content>6.8, 95%<jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>3.74\u201312.37) and an intermediate incidence in patients treated with adalimumab (<jats:styled-content style=\"fixed-case\">IRR<\/jats:styled-content>3.45, 95%<jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>1.82\u20136.55).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The difference in<jats:styled-content style=\"fixed-case\">TB<\/jats:styled-content>risk between<jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>inhibitors was similar with countries of low<jats:styled-content style=\"fixed-case\">TB<\/jats:styled-content>burden. This study suggests that particular attention is required for patients treated with<jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>monoclonal antibodies.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1756-185x.12530","type":"journal-article","created":{"date-parts":[[2015,1,3]],"date-time":"2015-01-03T05:46:06Z","timestamp":1420263966000},"page":"323-330","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Risk of tuberculosis in patients treated with anti\u2010tumor necrosis factor therapy: a nationwide study in South Korea, a\u00a0country with an intermediate tuberculosis burden"],"prefix":"10.1111","volume":"18","author":[{"given":"Seung Min","family":"Jung","sequence":"first","affiliation":[{"name":"Division of Rheumatology Department of Internal Medicine The Catholic University of Korea Seoul St. Mary's Hospital Seoul South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Hyeon","family":"Ju","sequence":"additional","affiliation":[{"name":"Division of Rheumatology Department of Internal Medicine The Catholic University of Korea Seoul St. Mary's Hospital Seoul South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mi\u2010Sun","family":"Park","sequence":"additional","affiliation":[{"name":"Clinical Research Supporting Center College of Medicine The Catholic University of Korea Seoul South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung\u2010Ki","family":"Kwok","sequence":"additional","affiliation":[{"name":"Division of Rheumatology Department of Internal Medicine The Catholic University of Korea Seoul St. Mary's Hospital Seoul South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung\u2010Su","family":"Park","sequence":"additional","affiliation":[{"name":"Division of Rheumatology Department of Internal Medicine The Catholic University of Korea Seoul St. Mary's Hospital Seoul South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ho\u2010Youn","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Rheumatology Department of Internal Medicine The Catholic University of Korea Seoul St. Mary's Hospital Seoul South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyeon Woo","family":"Yim","sequence":"additional","affiliation":[{"name":"Clinical Research Supporting Center College of Medicine The Catholic University of Korea Seoul South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung\u2010Hwan","family":"Park","sequence":"additional","affiliation":[{"name":"Division of Rheumatology Department of Internal Medicine The Catholic University of Korea Seoul St. Mary's Hospital Seoul South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,1,3]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22504"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.062760"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.091107"},{"issue":"2","key":"e_1_2_7_5_1","doi-asserted-by":"crossref","first-page":"ii37","DOI":"10.1136\/ard.62.suppl_2.ii37","article-title":"Role of tumour necrosis factor (TNF) in host defence against tuberculosis: implications for immunotherapies targeting TNF","volume":"62","author":"Ehlers S","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(08)70227-5"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011110"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21137"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.11137"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.118935"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24632"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200690"},{"key":"e_1_2_7_13_1","unstructured":"World Health Organization(2011)Global tuberculosis control: WHO report 2011. [Cited 30 July 2014.] Available from URL:http:\/\/www.who.int\/tb\/publications\/global_report\/2011\/gtbr11_full.pdf"},{"key":"e_1_2_7_14_1","unstructured":"Korea Centers for Disease Control and Prevention(2011)Trend of case notification rate per 100\u00a0000 by year. [Cited 30 July 2014.] Available from URL:http:\/\/www.knta.or.kr\/"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.22.2756"},{"key":"e_1_2_7_16_1","unstructured":"Korea Food & Drug Administration(2004)Guidelines for diagnosis and treatment of latent tuberculosis infection in patients with TNF antagonist (Korean). [Cited 30 July 2014.] Available from URL:http:\/\/www.mfds.go.kr\/index.do?mid=695&seq=687&cmd=v"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110373"},{"key":"e_1_2_7_18_1","first-page":"706","article-title":"Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers","volume":"34","author":"Seong SS","year":"2007","journal-title":"J Rheumatol"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI39143"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2010.04146.x"},{"key":"e_1_2_7_21_1","first-page":"40","article-title":"Differences between anti\u2010tumor necrosis factor\u2010alpha monoclonal antibodies and soluble TNF receptors in host defense impairment","volume":"74","author":"Dinarello CA","year":"2005","journal-title":"J Rheumatol Suppl"},{"key":"e_1_2_7_22_1","first-page":"1342","article-title":"The role of TST in the diagnosis of latent tuberculosis infection among military personnel in South Korea","volume":"10","author":"Choi CM","year":"2006","journal-title":"Int J Tuberc Lung Dis"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(04)00060-6"},{"key":"e_1_2_7_24_1","volume-title":"Korean Guidelines for Tuberculosis","author":"Joint Committee for the Development of Korean Guidelines for Tuberculosis Korea Centers for Disease Control and Prevention","year":"2011"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-011-1771-9"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199901283400401"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.28674"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(03)00382-2"}],"container-title":["International Journal of Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1756-185X.12530","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1756-185X.12530","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T21:34:46Z","timestamp":1747344886000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1756-185X.12530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,3]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["10.1111\/1756-185X.12530"],"URL":"https:\/\/doi.org\/10.1111\/1756-185x.12530","archive":["Portico"],"relation":{},"ISSN":["1756-1841","1756-185X"],"issn-type":[{"value":"1756-1841","type":"print"},{"value":"1756-185X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,3]]},"assertion":[{"value":"2015-01-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}